Impact on MPN Symptoms and Quality of Life of Front Line Pegylated Interferon Alpha-2a Vs. Hydroxyurea in High Risk Polycythemia Vera and Essential Thrombocythemia: Results of Myeloproliferative Disorders Research Consortium (MPD-RC) 112 Global Phase III Trial
Ruben A. Mesa(Atrium Health Wake Forest Baptist), Amylou C. Dueck(Mayo Clinic in Arizona), Lonette Sandy(Icahn School of Medicine at Mount Sinai), Adam J. Mead(National Institute for Health and Care Research), Damiano Rondelli(University of Illinois Chicago), Mohamed E. Salama(The University of Texas at San Antonio Health Science Center), Robert S. Hoffman(New York City Department of Health and Mental Hygiene), Craig M. Kessler(Georgetown University), Heidi Kosiorek(Mayo Clinic in Florida), Richard T. Silver(Cornell University), Josef T. Prchal(Huntsman Cancer Institute), Vesna Najfeld, Alessandro M. Vannucchi(Azienda Ospedaliero-Universitaria Careggi), Claire Harrison(Guy's and St Thomas' NHS Foundation Trust), Rona Singer Weinberg(University of North Carolina at Chapel Hill), Joseph Tripodi(Icahn School of Medicine at Mount Sinai), Casey L. O’Connell(University of Southern California), Valerio De Stefano(Agostino Gemelli University Polyclinic), Alessandro Rambaldi(Ospedale Papa Giovanni XXIII), Arnon Nagler(Sheba Medical Center), Marina Kremyanskaya(Tisch Cancer Institute), D Leibowitz(Sutter Health), Abdulraheem Yacoub(The University of Kansas Cancer Center), John Mascarenhas(Tisch Hospital), Mary Frances McMullin(Queen's University Belfast), Raajit K. Rampal(Memorial Sloan Kettering Cancer Center), Rosalind Catchatourian(John H. Stroger, Jr. Hospital of Cook County), Andrea Bacigalupo(Università Cattolica del Sacro Cuore), Joanne Ewing(Heart of England NHS Foundation Trust), Elliott F. Winton(Emory University), Jean‐Jacques Kiladjian(Délégation Paris 5), Dmitriy Berenzon(Atrium Health Wake Forest Baptist), Murat O. Arcasoy(Duke University)
Cited by 12
Related Papers
Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis
|Cancer Cell|2005|3k
International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data
|Blood|2022|2.8k
Symptom Monitoring With Patient-Reported Outcomes During Routine Cancer Treatment: A Randomized Controlled Trial
|Journal of Clinical Oncology|2015|2.6k